Navigation Links
2 immune-system proteins linked to colitis-associated cancer

Recent research from the laboratory of Michael Karin, PhD, at the University of California, San Diego School of Medicine the first researcher to demonstrate a molecular link between inflammation and cancer has identified two potential targets for the prevention and treatment of colitis-associated cancer (CAC), the most serious complication of inflammatory bowel disease.

Karin, Distinguished Professor of Pharmacology and Pathology and member of the Moores UCSD Cancer Center, and his team used genetic tools to demonstrate in mice that a cytokine called Interleukin 6 (IL-6), is an important regulator of tumor production during CAC development, and that its molecular effects are largely mediated by the transcription factor STAT3 in cancer cells. Their latest study which is also the first to establish the cancer-promoting function of STAT3 in a validated mouse model of human cancer will be published in the February 3 on-line edition of the journal Cancer Cell.

Recurrent inflammation and chronic infections contribute to a large number of different cancers including CAC which occurs in people suffering from chronic colitis, a common inflammatory bowel disease, putting them at very high risk for cancer. Cytokines small proteins released by immune-system cells have been suggested to drive early tumor growth by stimulating the growth and survival of pre-malignant cells.

In previous work, Karin's team showed that activation of a pro-inflammatory protein called NF-kB stimulates the proliferation of premalignant epithelial cells in CAC, giving rise to malignant growths in the colon. Interestingly, NF-kB in colonic epithelial cells promotes the development of cancer, not through inflammation, but through inhibition of apoptosis or cell death. On the other hand, NF-kB in the immune cells promotes cancer by enhancing inflammation, mostly by controlling the expression of pro-inflammatory cytokine expression. One of these cytokines was thought to be IL-6.

"IL-6 fosters chronic inflammation and malignant cell survival and growth by regulating the survival of T cells, white blood cells that direct the body's immune system," Karin said.

The proliferative and survival effects of IL-6 are largely mediated by the transcription factor STAT3, first suggested to have a cancer-promoting function by James Darnell at Rockefeller University in New York. The new work, which provides the first genetic evidence for the critical role of STAT3 in cancer using a mouse model of human cancer, also suggests that IL-6 and Stat3 constitute useful targets for the prevention and treatment of CAC, Karin added. The researchers showed that ablation of STAT3 in intestinal epithelial cells effectively inhibited CAC induction and growth in mice.

Colorectal cancer is one of the most common fatal malignancies worldwide, and almost half of all affected individuals die from the disease. Patients with inflammatory bowel disease, such as ulcerative colitis, are at a higher risk of developing colorectal cancer.


Contact: Debra Kain
University of California - San Diego

Related medicine news :

1. Preeclampsia May Stem From Malformed Proteins
2. Spinal fluid proteins signal Lou Gehrigs disease
3. 2 Cardiovascular Proteins Tied to Severity of Alzheimers
4. Two cardiovascular proteins pose a double whammy in Alzheimers
5. Stopping ovarian cancer by blocking proteins coded by notorious gene
6. Mutant proteins result in infectious prion disease in mice
7. Quintet of proteins forms new, early-warning blood test before heart attack strikes
8. Elaborate Network Drives When and Where Proteins Are Made
9. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
10. Pressured proteins: A little pressure in proteomics squeezes 4-hour step into a minute
11. Discovery of key malaria proteins could mean sticky end for parasite
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... Purdue University announced Tuesday (Oct. 13) ... aimed at enhancing Purdue’s life sciences research and graduate education. The initiative comes ... The investment will result in cohesive efforts across several colleges and is designed ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... focused on cancer patients, today announced a new partnership with the International ... this rare type of non-Hodgkin’s lymphoma, their families and physicians. , “Waldenstrom’s ...
(Date:10/13/2015)... ... October 13, 2015 , ... HealthAware , headquartered ... Patient Engagement Summit . HealthAware is a technology company focused on the ... interventions via mobile devices that provide a framework for the development of healthy ...
(Date:10/13/2015)... Texas (PRWEB) , ... October 13, 2015 , ... Symposium ... for the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, ... place immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , ...
(Date:10/13/2015)... ... 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood , ... The research, which was conducted at the Dental Institute at King's College London in ... stress during pregnancy and future dental health in the child. For years, researchers have ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  Human Longevity, Inc. (HLI), ... of medicine, announced today the launch of the company,s ... that has the potential to transform healthcare. The inaugural ... CA , at HLI,s headquarters facility. More Health ... other US and International cities. ...
(Date:10/13/2015)... , Oct. 13, 2015  Synapse Biomedical Inc. ( ... Approval Study (PAS) studying the use of the NeuRx ... continuing to enroll patients. the United ... the FDA market-approved criteria. The PAS study group met ... 2014. The study has since expanded the enrollment target ...
(Date:10/13/2015)... Oct. 13 2015 ... of the "US & European Markets ... (2010-2021)" report to their offering. ... addition of the "US & European ... Countries (2010-2021)" report to their offering. ...
Breaking Medicine Technology: